2026 Future XDC New Drug Conference (Day 2)-TONACEA

2026 Future XDC New Drug Conference (Day 2)

Time：

March 26–27

Place：

成都

label：

2026,行业会议

Popularity：

Chengdu in March is brimming with spring vitality and surging with innovation.

On March 27th, the second day of the highly anticipated 2026 Future XDC New Drug Conference hosted by Tongxieyi, the venue remained packed with attendees, and the enthusiasm showed no signs of waning.

From capital trends and CMC technological breakthroughs to evidence-based clinical exploration and AI-driven paradigm shifts, in-depth collisions between R&D and transformation ran throughout the conference. The thematic presentations and engaging exchanges in each parallel session converged into a mighty river propelling the XDC new drug industry forward.

Here, every presentation is an inquiry into the cutting edge, and every dialogue is a depiction of the future. Attendees seized opportunities in the clash of ideas and sought breakthroughs amid technological iteration, jointly witnessing the boundless potential of XDC drugs moving toward "diversified integration, everything can be conjugated".

This conference is not only a concentrated showcase of industry wisdom but also charts a new course for the development of XDC new drugs in China and across the globe. We will meet again in Chengdu Medical City next March to continue this annual promise about the future of antibody-drug conjugates!

Report on the First Day of the 2026 Future XDC New Drug Conference

Live | Thousands Gather in Tianfu, Exploring the Future of "Core" and "Conjugation" in New Drugs

Report on the First Day of the 2026 Future XDC New Drug Conference：Live | Thousands Gather in Tianfu, Exploring the Future of "Core" and "Conjugation" in New Drugs

TONACEA

Future ADC and Antibody New Drug Conference

From initial targets to commercial endgames, from laboratory molecules to blockbuster drugs in the global market, ADC and antibody new drugs have never been confined to breakthroughs in a single technology. Today's four parallel sessions span the entire chain of new drug R&D, exploring the logic of breakthrough in this era through the collision of capital, CMC, clinical development and AI.

Session 3

Global Expansion, Investment and Financing

This session focuses on the key topics in the wave of global expansion within the conjugate drug sector, centering on the transformation from technological advantages to commercial value.

Distinguished guests from institutions including Fuxi Capital, Xingze Capital, and SDIC Innovation analyzed how capital empowers cutting-edge technologies to go global, from perspectives such as the future prospects of AOCs, investment and financing trends in conjugate drugs, and the resonance between capital and industry in innovative pharmaceuticals. Yiduo Cloud and Sunshine Novo shared practical industrialization experience around topics including digital intelligence-enabled commercialization and extrahepatic targeted delivery of small nucleic acids.

Sullivan Consultancy analyzed the current status of XDC investment and financing as well as global expansion trends through data, pointing out that Chinese XDC enterprises are shifting from single technology export to a diversified cooperation model.

The roundtable discussion was moderated by Wu Qinggong, Vice President of the China Pharmaceutical Enterprise Management Association, with guests from CICC Guoxin, Huatai Zijin, Boyuan Capital, Roche China and other institutions participating. Amid the global competitive landscape, the collaborative innovation between capital and industry is opening up a broader channel for Chinese XDC enterprises.

部分与会嘉宾合影

Session 4

CMC Challenges and Commercialization Insights

Co-organized by: NanoMicro Technology

If target discovery and molecular design represent the "from 0 to 1" stage of new drug R&D, then CMC is the critical leap to achieve "from 1 to 100". This session focused on the pain points and solutions in the scaled-up manufacturing of ADC and conjugate drugs, presenting a complete picture of their transition from laboratory research to large-scale production.

Representatives from enterprises including WuXi XDC, NanoMicro Technology, NOvagen, and Hangstown Biologics shared their breakthrough progress and practical experience in the CMC field, covering topics such as analytical method development, full-process purification solutions, next-generation solid tumor therapeutic product development, and modular manufacturing. WuXi AppTec and May-Bio demonstrated how upstream technologies provide solid support for downstream commercialization from the perspectives of integrated process development and empowerment at the culture medium source.

The roundtable discussion was moderated by Wu Yuntao, CTO of Macromolecular Products at NanoMicro Technology, with executives from Zhongsheng Ruichuang, Tangling Biologics, Dongyao Pharmaceutical, and Haoyuan Biologics participating. Against the backdrop of industrial upgrading and technological iteration, as XDC drugs enter the commercial volume ramp-up phase, establishing a full-chain quality control system from source to terminal has become the core competitiveness for enterprises to win the market.

部分与会嘉宾合影

Session 5

Preclinical Evaluation and Clinical Development

Clinical development is the "Darwinian Sea" that every new drug must cross. This session brought together dual perspectives of preclinical and clinical development, focusing on core issues of novel conjugate drugs during the human study stage.

Dr. Julie Wu, CMO of ImmuneOnco Biopharma, shared her insights on the clinical development strategy of PD-1/VEGF bispecific antibodies. Dr. Chen Zhaorong, Chief Medical Officer of HomaMed, systematically analyzed the challenges faced in ADC clinical development and proposed the need to establish differentiated development pathways based on their unique mechanisms of action.

Representatives from LIDE Biotech, STA Pharmaceutical, Innostar, and WuXi AppTec presented the complete R&D chain of conjugate new drugs from laboratory to clinic, covering dimensions including preclinical efficacy evaluation, highly potent polymer process development, key considerations in nonclinical evaluation, and DMPK analysis strategies.

部分与会嘉宾合影

Session 6

New Drug R&D in the Era of AI Large Models

Co-organized by: Zhongcheng Jiulian

AI large models are engaging in the entire new drug R&D chain with unprecedented depth. This session brought together industry experts from diverse backgrounds, including AI drug discovery startups and traditional pharmaceutical companies, showcasing the latest progress of this transformation.

Shuangyun Biotech, DeepMind Technology, and Huawei Pharma Legion depicted how AI reshapes the logic of new drug R&D at the fundamental level, from the perspectives of AI as the engine for innovation-driven discovery, the forward-looking vision of "creating AI scientists", and the industrial ambition of building the "Second Technology Plane".

In terms of full-process applications, Tushen Zhihe, Yidu Cloud Technology, Segsci, and Megarobotics presented the practical implementation of AI across the entire new drug R&D chain, covering scientific agents, clinical trial management, organoid plus AI empowerment, and multi-agent collaboration.

The roundtable discussion was moderated by He Qi, Co-founder and CEO of Tenmai Pharma, with representatives from Qilu Pharmaceutical, Sinovet, Salubris, and HaiCo Pharmaceutical jointly exploring the past, present, and future of XDC innovation. The deep integration of AI and drug R&D is driving innovation to shift from "trial-and-error driven" to "prediction driven", and human-machine collaboration will become the new normal in new drug R&D.

部分与会嘉宾合影

TONACEA

Future Nuclear Medicine Conference

When radionuclides meet precise targeting, the battlefield of nuclear medicine is shifting from individual technological breakthroughs to competition in the entire ecosystem. Today's two nuclear medicine-themed sessions – one anchoring R&D directions from a cliniceal perspective, the other focusing on building industrial foundations to enhance translation capabilities – together outline a clear path for China's nuclear medicine industry to evolve from fragmented exploration to systematic development.

Session 9

Nuclear Medicine Clinical Stratgy

分会主席及策划：石洪成

复旦大学附属中山医院核医学科主任

中华医学会核医学分会候任主委

分会策划

须　涛

智核生物创始人、CEO

同写意核药俱乐部秘书长

分会主持

苑大为

北京夸克医药集团创始人、董事长兼总经理

Founder, Chairman & General Manager, Beijing Quark Pharmaceutical Group

Clinical strategy for nuclear medicine serves as a critical bridge connecting target discovery to patient benefits. This session brought together core forces from frontline nuclear medicine clinics and the industry in China, to explore how clinical needs can be integrated earlier into nuclear medicine R&D, achieving closer medical-industry collaboration.

Leading clinical experts from Zhongshan Hospital Fudan University, Fudan University Shanghai Cancer Center, Beijing Gaobo Hospital and other institutions outlined the overall landscape and direction of nuclear medicine clinical translation, covering the current development of nuclear medicine in China, clinical problem-driven radiopharmaceutical R&D, and precision molecular imaging. Representatives from The Affiliated Hospital of Southwest Medical University, The First Affiliated Hospital of Xiamen University, Honghong Pharmaceutical and others shared abundant clinical data and translational experience focusing on hot areas including ¹⁷⁷Lu/²²⁵Ac, FAP therapeutic drugs, and tumor radiopharmaceutical therapy.

Enterprise representatives from United Imaging Healthcare, Minuteman Biotech and others demonstrated how technological tools empower nuclear medicine clinical research from the perspectives of AI imaging analysis and clinical imaging analysis platforms.

The roundtable discussion was moderated by Zhang Jinming, Researcher and PhD Supervisor of the Department of Nuclear Medicine, The First Medical Center of Chinese PLA General Hospital. In-depth exchanges were conducted between clinical experts and industry representatives from Tongrui Bio, Jinfeng Laboratory and others, exploring how nuclear medicine R&D can better respond to real clinical needs from a clinical perspective.

部分与会嘉宾合影

Session 10

Nuclear Medicine CMC and Non-Clinical Strategy

分会策划

李建国

中国辐射防护院安全评价中心书记

分会主持及策划

蔡继鸣

纽瑞特医疗联合创始人、董事长、总裁

The uniqueness of nuclear medicine lies in its dual attributes as both a "pharmaceutical product" and a "radionuclide", which sets extremely high thresholds for its CMC and non-clinical evaluation. This session focused on the "infrastructure engineering" of nuclear medicine from laboratory to industrialization, presenting systematic challenges and practical solutions in R&D translation, regulatory registration, quality control and other aspects of this sector.

The China Institute for Radiation Protection, Saifu Guotong and others shared systematic thinking on nuclear medicine safety evaluation from the perspectives of integrated non-clinical R&D translation strategies and key points of non-clinical safety assessment.

The Institute of Nuclear Physics and Chemistry, China Academy of Engineering Physics, Heyuan Bio, Mednovo Medical and others showcased cutting-edge progress in novel radionuclide and drug development, focusing on innovative R&D of domestic medical isotopes, targeted ²¹¹At radiopharmaceutical development, and prospects for terbium-161 radionuclides.

In terms of industrialization and compliance, enterprise representatives from Jingjia Hang, Tongrui Bio, Chutian Technology and others presented key supporting forces for nuclear medicine industrialization from the dimensions of CMC registration innovation, full-chain quality control practices, and automation & intelligence of nuclear medicine equipment.

Establishing internationally aligned quality systems and evaluation standards is an important cornerstone for China’s nuclear medicine to step onto the global stage. In the roundtable discussion, representatives from Neurite Medical, Heyuan Bio, Sintong Pharmaceutical, Yunnan Baiyao, CNNC High-Tech and other enterprises conducted in-depth exchanges on the construction of China’s nuclear medicine CMC and non-clinical capabilities from an international perspective.

部分与会嘉宾合影

TONACEA

Visit to Chengdu Medical City

A Journey Tracing the Origins of the XDC Industry

Experience is better than theory. To touch the real pulse of innovation and step into the frontline of the XDC industry, the conference specially organized the "Wenjiang High-Tech Zone ADC/RDC Industry Tour". Tongxieyi and visiting guests went deep into Chengdu Medical City, successively visiting the Industrial Planning Exhibition Center of the Biomedicine Zone in Wenjiang High-Tech Zone, representative enterprises in the ADC field, and radiopharmaceutical CDMO platforms, experiencing the complete landscape of the XDC industry from R&D to commercialization from multiple dimensions.

From Kelun Botai, which has set a record for Chinese new drugs going global, to Grand Pharmaceutical Nuclear Medicine R&D and Production Base, and then to Tongrui Bio, a leading nuclear medicine CDMO enterprise, the backbone forces of ADC/RDC converge here, jointly outlining the complete chain of the XDC industry from R&D to production. Chengdu Medical City’s ambition to build a national XDC industry highland is clearly visible.